Xgeva (Denosumab) Rejected By the FDA for Use in Men with Advanced Prostate Cancer Who Do Not have Bone Mets
Xgeva (denosumab), which has already been approved by the Food and Drug Administration (FDA) for the prevention fractures in men with advanced prostate cancer that has already migrated to the bone, has been rejected by [...]
Become A CDMRP Reviewer and Influence the Direction of Prostate Cancer Research
The Prostate Cancer Research Program (PCRP) of the Department of Defense, Congressionally Directed Medical Research Programs (CDMRP) has received our fiscal year 2012 (FY12) funding to support research projects in the prevention, detection, diagnosis, and [...]
Early Hormone Therapy Delays Disease Progression in Advanced Prostate Cancer
Despite the fact that we have had good research for well over 15 years that show that early hormone therapy increases over all survival, some doctors still insist on delaying the start of hormone therapy. [...]
The New Yorker Magazine Publishes A Great Article on Immunotherapy
For those who might be interested in the April 23, 2012 edition of The New Yorker Magazine, Jerome Groopman has written an excellent article on the history and current state of Immunotherapy. The article is [...]
From 2012 AACR Meeting – Resveratrol Effects Prostate Cancer Cells
Resveratrol (3,4’-trihydroxystilbene) is a natural product that can be found in significant concentrations food products like red wine, peanuts, walnuts etc. There have been some evidence that indicates that resveratrol has anti-tumorigenic activity, including in [...]
From the 2012 AACR Meeting – Pomegranate components modulate distinct pathways in prostate cancer cells
Pomegranate juice has long been in the folklore of prostate cancer survivors. Many of us use it with the goal of controlling our PSA. Most of the research evaluating the ability of pomegranate juice to [...]